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ABSTRACT 
Objective: NSAIDs are very hydrophobic drugs and have low solubility. This causes the bioavailability of NSAIDs to be low in the body thus affect its 
anti-inflammatory activity. There has been some primary research proven that solid dispersion can increase the solubility and anti-inflammatory 
activity of NSAIDs. Moreover, there are not researches explaining the effect of a solid dispersion system on the anti-inflammatory activity of NSAIDs. 
Therefore, it is necessary to conduct a review to assess the effect of the solid dispersion system on the solubility and anti-inflammatory activity of 
NSAIDs systematically.  
Methods: This was systematic review research, where the data were originated from PubMed and Science Direct with the keywords ‘NSAID’, ‘solid 
dispersion’, and ‘drug effect’. The inclusion criteria formulated were English-language papers, published in 2010–2020, and primary research that 
conducted in vivo anti-inflammatory testing. The appropriate papers by the inclusion criteria were assessed its quality by the SYRCLE’s tool. Data 
was analyzed narratively.  
Results: The results were eight papers under the inclusion criteria. As a whole is known modification of solid dispersion can increase the 
dissolution profile of NSAIDs. This is because the polymer used can increase the wetting of drug particles, thereby being able to increase the 
solubility of NSAIDs.  
Conclusion: The anti-inflammatory activity of NSAIDs by solid dispersion systems are increases compared to NSAIDs without solid dispersions. 
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INTRODUCTION 
NSAIDs are highly hydrophobic compounds, 15 from 18 NSAIDs are 
known belong to the Biopharmaceutics Classification System (BCS) 
Class II, which has low solubility and high permeability. Some 
examples of NSAIDs in BCS Class II are ibuprofen, mefenamic acid, 
aceclofenac, dan meloxicam. NSAIDs that are not included in BCS 
Class II are ketoprofen, ketorolac, and aspirin [1]. Solubility is 
important because it can affect the therapeutic effect of the drug. 
Drugs with low solubility can provide poor absorption values, 
thereby affecting the bioavailability of drugs in the body [2, 3]. In 
vitro bioavailability of drugs in vitro can generally be known through 
dissolution testing, because ideally, drug dissolution in vitro 
correlates with the bioavailability of drugs in vivo [3]. One strategy 
to increase solubility is by solid dispersion. Solid dispersion was 
chosen because it can increase solubility or dissolution rate, reduce 
particle size, increase a wettability area, and increase the 
bioavailability of drugs [4, 5]. 
Solid dispersions have been widely applied and are proven to be 
able to modify the solubility of NSAIDs with various types of 
polymers and methods of making solid dispersions. Some methods 
for making solid dispersions include a melting method, solvent 
evaporation, spray drying, microwaves irradiation, hot-melt 
extrusion, and kneading method. Research conducted by Chen et al., 
make modifications with the solid dispersion system against 
ibuprofen-urea by the melting method [6]. In another study, a 
piroxicam-PEG 4000 solid dispersion system was made using the 
solvent evaporation method [7]. The spray drying method is used in 
making celecoxib solid dispersions with isomalt polymers and PVP-
K30 [8]. Research conducted by Shi et al. making indomethacin-
soloplus solid dispersions by various methods, including 
microwaves irradiation and hot-melt extrusion [9]. In addition, the 
manufacture of ketoprofen solid dispersions with polymers PVP-K30 
and D-mannitol using the kneading method [10]. Modification of 
solid dispersion can improve the solubility of NSAIDs and cause an 
increase in anti-inflammatory activity. This was proven through 
research conducted by Shazly, showed an increase in anti-
inflammatory activity in sulindac after it was made in a solid 
dispersion system [11]. 
Based on the description above, it can be seen that there have been 
many primary studies that have conducted tests to see the effect of a 
solid dispersion system on NSAID solubility. However, there are no 
studies that conclude the effect of the overall solid dispersion 
system, especially on the anti-inflammatory activity of NSAIDs. A 
review is needed to assess systematically the effect of the solid 
dispersion system on the anti-inflammatory activity of NSAIDs. 
MATERIALS AND METHODS 
Paper search and selection strategy 
A paper search was carried out comprehensively in the PubMed and 
Science Direct databases to obtain papers relevant to the purpose of 
this study. The combination of keywords used is "NSAID" AND "solid 
dispersion" AND "drug effect". Paper matches the inclusion criteria 
analyzed, which is in English in the range 2010-2020 and conduct 
primary research with in vivo anti-inflammatory testing. Exclusion 
criteria in this study are papers that cannot be accessed full-text and 
duplicate papers (papers from PubMed and Science Direct with the 
same author, title, and abstract) and the paper selected with an 
earlier publication year. 
Paper quality assessment and data synthesis 
This paper included in the inclusion criteria then it is necessary to 
assess a quality of the paper by determining the critical appraisal 
analysis and assess a validity of the research conducted. Especially 
in studies that use test animals need to be analyzed related to the 
risk of bias during the research process [12]. Recommended tools 
for animal study can use the Systematic Review Centre for 
Laboratory animal Experimentation’s (SYRCLE) [13]. There are ten 
domains in SYRCLE’s tool and each domain can be answered with 
"YES", "UNCLEAR", or "NO". The answer "YES" indicates a low risk of 
bias. The data obtained will be analyzed by meta-synthesis or 
narrative. 
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RESULTS AND DISCUSSION 
There are 777 papers obtained through PubMed and Science 
Direct databases with the keywords used. The first screening is 
based on the title and abstract of the NSAID-related paper that is 
modified with solid dispersion.  
The results of the papers that passed the title and abstract 
selection were 161 papers. From these papers, 153 papers were 
excluded because there is no in vivo anti-inflammatory testing and 
8 papers were obtained that fit the inclusion criteria (fig. 1) and 
subsequently an assessment of the quality of the paper based on 
the risk of bias. 
 
 
Fig. 1: Paper selection algorithm 
 
Based on the results of the bias risk assessment above, it can be seen 
that all papers have a "low risk of bias" criteria for sequence 
generation domains, baseline characteristics, allocation concealment, 
random housing, blinding (assessor), incomplete outcome, selective 
outcome, and others. Whereas there are two “unclear” domains, 
namely blinding (caregiver) and random outcome assessment (fig. 2). 
The domain of blinding (caregiver) is said to be "unclear" because all 
the paper does not explain in detail related to the condition of the 
caregiver during the intervention given, whether the caregiver knows 
the treatment given to each animal. Whereas in the random outcome 
assessment domain it is said to be "unclear" because it is not explained 
related to the way of taking test animals to assess the outcome 
whether the test animals are chosen randomly or not. However, in 
each paper, it has been explained that control and treatment test 
animals are assessed in the same way to obtain outcomes. The SYRCLE 
tool was developed from the Cochrane Risk of Bias tool and has been 
adjusted to assess the risk of bias in research with test animals [14]. 
The Cochrane Risk of Bias tool is not recommended for calculating 
total scores or using a scale in interpreting assessment results. This 
causes reviewers who use this tool to assess the 'domain key' which is 
the most critical in determining the results, for example in research 
related to pain, the blinding domain can be chosen as the 'domain key' 
[15]. In this study, the 'domain key' is blinding (assessor) because the 
outcome assessment method must be the same and be assessed in 
each test animal in order to obtain accurate results. Domain blinding 
(assessor) in all papers included in the category of low risk of bias, it 
can be interpreted that all papers used have accurate results because 
they are not disturbed by the risk of bias. 
 
 
Fig. 2: Risk of bias assessment result 
 
Based on the paper according to the inclusion criteria, several NSAIDs 
were modified with a solid dispersion system, including ibuprofen, 
aceclofenac, meloxicam, mefenamic acid, flufenamic acid, celecoxib, 
sulindac, and flurbiprofen. All NSAIDs used in these eight papers are 
included in BCS class 2 [1, 16]. Solid dispersions in NSAIDs can be used 
with various types of polymers and manufacturing methods (table 1). 
             | 2
Yugatama et al. 
Int J App Pharm, Vol 13, Special Issue 3, 2021, 1-6 
4th International Seminar on Pharmaceutical Science and Technology 2020 
Table 1: NSAIDS with solid dispersion modification 
Author NSAIDs Solid dispersion method Polymers % drug release after 60 min 
Solid dispersion Non-solid dispersion 
6 Ibuprofen Melt method Urea 85 55 
17 Aceclofenac Solvent evaporation Crospovidone - - 




18 Flubiprofen Melt method Urea 42 11 
11 Sulindac Solvent evaporation PVP 40000 100 48 
20 a. Mefenamic Acid 
b. Flufenamic Acid 




24 Mefenamic Acid Hot-melt extrusion Eudragit EPO 99 1 *) 
27 Celecoxib Solvent evaporation Aerosil 64 27.7 **) 
Note: the dissolution test data were taken from previous research *) [25] dan **) [32] 
 
Research conducted by Chen et al. making ibuprofen-urea solid 
dispersions with several comparisons. This solid dispersion is made 
by the melt method. The dissolution test is carried out using 
apparatus II (paddle) with ibuprofen non-solid dispersion (NSD) and 
ibuprofen solid dispersion (SD) with ratio 1:1; 1:2; 1:5; dan 1:10. 
The results of the percentage of drug release after 60 min are 
ibuprofen NDP<DP 1:1<DP 1:2<DP 1:5<DP 1:10. The solubility of 
ibuprofen is increasedby improving the ratio of urea to ibuprofen 
[6]. Another research from Jana et al. using only one comparison in 
aceclofenac-crospovidone solid dispersion that is 1:4 by the solvent 
evaporation method and then formed in a gel preparation. In this 
study, the dissolution test was not carried out, but a saturation 
solubility test was performed which compares aceclofenac NSD and 
SD. The saturation solubility test is done by dissolving aceclofenac in 
phosphate buffer saline pH of 7.4 so that the concentration of the 
drug dissolved in the media can be obtained. The results obtained 
are 0.248±0.020 mg/ml for aceclofenac SD and 0.091±0.012 mg/ml 
for aceclofenac NSD. This shows that the presence of solid dispersions 
can provide better saturation solubility [17]. On research from 
Malipeddi et al. flurbiprofen is made of solid dispersions with urea or 
mannitol polymers using the melt method. Flurbiprofen-urea SD and 
flurbiprofen-mannitol SD were made by comparison, respectively 
1:0.5; 1:1; dan 1:2. The dissolution test was carried out on acid media 
(0.1 N HCl) with flurbiprofen NSD samples, flurbiprofen-urea SD, and 
flurbiprofen-mannitol SD. The percentage of drug release on 
flurbiprofen NSD is 11% after 60 min. While the best percentage of 
drug release of ratio 1:2, in the flurbiprofen-urea SD is 42% while in 
the flurbiprofen-mannitol SD is 35% after 60 min [18]. This is due to 
the high wetting effect of urea and urea have high solubility in water 
and other organic solvents [19].  
Sulindac solid dispersions are made with two polymers, they are 
PEG 6000 or PVP 40,000 at a ratio of 1:1; 1:2; 1:3; and 1:5 with 
solvent evaporation method. Dissolution test use apparatus II 
(paddle) in phosphate buffer media (pH 6.8). The percentage of drug 
release in sulindac NSD was 48% after 60 min. In solid dispersions, 
the best results are obtained from a ratio of 1:5 either with a 
polymer PEG 6000 or PVP 40,000. This shows that the increasing 
proportion or ratio of polymers can increase the dissolution rate. 
But between the two polymers used the best drug release results 
were with 100% PVP polymer at 100% while PEG 6000 gave a yield 
of 82%. That is because PVP can inhibit the formation of 
crystallization conditions. PVP plays a role in providing 
antiplasticizing effects by decreasing the diffusion of drug molecules 
and increasing viscosity in solid dispersion systems to form lattice or 
lattice [11]. Solid dispersion in research from Alshehri et al. namely 
mefenamic acid and flufenamic acid made with pluronic polymer 
F127, eudragit EPO, PEG 4000, or gelucire 50/13 1:5 ratio with 
microwaves irradiation method. The dissolution test was carried out 
with apparatus II (paddle) on phosphate buffer dissolution media 
(pH = 7.4). The result of the percentage release of mefenamic acid in 
NSD was 9% and in flufenamic acid was 68% after 60 min [20]. 
Gelucire 50/13 polymer provides the lowest dissolution release 
because gelucire 50/13 is a partial hydrophobic polymer [21]. While 
the EPO eudragit polymer showed an increase in the dissolution rate 
in the first 5 min, but overall showed a slowdown in the dissolution 
rate. This is due to the fact that Eudragit EPO has a high swellable, 
permeable, and solubility ability in gastric media (pH 1.2-5), so it has 
a low solubility at pH 7.4 [22, 23]. Different results are shown in 
pluronic polymers F127 and PEG 4000 because they provide the 
highest release compared to the other two polymers. The percentage 
of SD release for mefenamic acid was 89% and 90% for the PEG 4000 
polymer and pluronic F127, respectively. While the percentage of SD 
release of flufenamic acid was 87% and 82% for the polymer PEG 
4000 and pluronic F127, respectively. This is due to the role of 
hydrophilic or water-soluble polymers that surround or surround the 
crystalline particles of mefenamic acid and flufenamic acid. So that it 
can increase the surface area of dissolution media and cause an 
increase in dissolution rate. Based on these results obtained %DE60 
for mefenamic acid-PEG 4000 SD at 61.18% and %DE60 for flufenamic 
acid-PEG 4000 SD at 59.40%, the best polymer is PEG 4000. 
The manufacture of mefenamic-eudragit acid solid dispersion EPO is 
carried out by Alshehri et al. with 20% and 25% mefenamic acid 
content in solid dispersions by the hot-melt extrusion method [24]. 
Previous research by Alshehri et al. discussed the dissolution test 
with the same formula. Mefenamic acid-eudragit EPO SD is made in 
orally disintegrating tablets (ODT) preparations. The dissolution test 
was carried out with apparatus II on acetate buffer media pH 5.5. 
The result of mefenamic acid release in NSD was 1%, whereas in the 
mefenamic acid-eudragit EPO SD with 20% mefenamic acid content 
was 99% after 60 min. There are similar results at SD 25%, namely 
the percentage of the release of 90% [25]. This is because the EPO 
eudragit functions as a proton acceptor because it contains a tertiary 
amino group other than the carbonyl group so that the EPO eudragit 
can form bonds with mefenamic acid as a proton donor. Then the 
aminoalkyl groups in the eudragit EPO side-chain play a role in the 
formation of amorphous mefenamic acid in solid dispersions [23]. In 
theory, the amorphous form can provide higher solubility compared 
to the crystal form [26]. 
There are two studies that tested mefenamic acid with the same 
polymer, eudragit EPO with different methods of making dissolution, 
and gave different results. That is caused by research conducted by 
Alshehri et al. (2015) aims to make mefenamic acid in ODT 
preparations, so that the dissolution media used are in accordance 
with the saliva pH (buffer acetate pH 5.5) which is different from 
research by Alshehri et al. (2019). This results in different release 
results when SD of mefenamic-eudragit acid EPO on phosphar buffer 
media pH 7.4 and acetate buffer pH 5.5 because the solubility of 
eudragit EPO is greatly affected by media pH [20, 25].  
Research conducted by Choi et al. making celecoxib solid dispersions 
using a carrier (aerosil), solubilizer (polyoxyl 15 hydroxy 
stearate/HS 15), and alkalizer (meglumine) with the solvent 
evaporation method [27]. Previous research by Choi et al. 
dissolution test is carried out with the same formula. The dissolution 
test was carried out using apparatus II (paddle) on HCl dissolution 
media pH 1.2, distilled water, and phosphate buffer pH 6.8. The 
results of the percentage release of celecoxib NDP 60 min in 
dissolution media pH 1.2 is 12.4% and in celecoxib, DP is 27.2%. The 
results of the percentage release of celecoxib NSD in the distilled 
water media were 15.9% and in celecoxib, SD was 47.7%. While the 
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results of the percentage release of celecoxib NSD on dissolution 
media pH 6.8 was 27.7% and on celecoxib SD was 64% after 60 min 
[28]. This shows that the best release of celecoxib at pH 6.8. In line 
with research by Ghanavati et al. which makes celecoxib SD with K-
30 PVP polymer and isomalt. The results obtained indicate that the 
percentage of celecoxib SD release in alkali or alkaline dissolution 
media is higher [8]. That is because the base media has more 
hydroxyl groups so that the-OH group can break the intermolecular 
hydrogen bonds at celecoxib. Then the water molecule or H2O can 
form hydrogen bonds with celecoxib and cause celecoxib to be more 
hydrated. The increase in dissolution percentage in celecoxib SD is 
due to the amorphous form of celecoxib and hydrogen bonding 
between celecoxib and the excipients used [28]. 
In other studies using a polymer PEG 6000 (hydrophilic polymer), 
gelucire 50/13 (surfactant), and pluronic F68 (surfactant). A binary 
system meloxicam solid dispersion is made in a ratio of 1: 0.25. 
While the solid dispersion with quarternary system combines three 
polymers, namely meloxicam: gelucire 50/13: PEG 6000: pluronic 
F68 with a ratio of 1: 0.25: 0.25: 0.25 and 1: 0.5: 0.5: 0.5 The 
dissolution test was carried out with apparatus II (paddle) on a 
medium of 0.1 N HCl pH 1.2 and 0.2 M phosphate buffer pH 7.4. The 
results of the percentage release of meloxicam NSD on HCl media 
were 2.2% and on the phosphate buffer media of 8% after 60 min. In 
HCl media, it is known that the best percentage of release is on SD 
quarternary system with a ratio of 1: 0.5: 0.5: 0.5 which is equal to 
60% after 60 min. This is due to the synergistic effect between the 
hydrophilic polymer and the surfactant used. Hydrophilic polymers 
function to increase wettability and surfactants function to reduce 
the surface tension of dissolution media. Whereas in phosphate 
buffer media, both SD binary system and the quarternary system 
give a percentage of release up to 100% [29]. That is because 
meloxicam is practically insoluble in water and with a low pH, so its 
solubility will increase with increasing pH of the solution [1].  
Overall it can be seen that a solid dispersion system can increase the 
dissolution profile of NSAIDs due to several things below [6, 20, 29]: 
a. Polymer used in the manufacture of solid dispersions is 
hydrophilic polymers (example: urea, crospovidone, mannitol, PEG, 
PVP, etc.) because they can increase the wetting of drug particles, 
thereby causing a decrease in aggregate and agglomeration of 
particle. 
b. The more proportion of polymer used can give a better 
dissolution profile. The amount of polymer used must also be 
adjusted to the maximum dose of polymer in the body [30]. Based on 
the eight papers discussed, it is known that the ratio between the 
drug and the highest polymer tested is 1:10. 
c. Solid dispersions can change the initial form of NSAIDs in the 
form of crystals into amorphous forms or reduce the shape of 
crystals due to the formation of molecular interaction between 
NSAIDs and the polymers used.  
d. Solid dispersion with a quarternary system has a synergistic effect 
between the polymers used so it can increase the dissolution rate. 
The mechanism for releasing drugs from solid dispersions is 
complex because it not only looks at the NSAID profile but also 
needs to pay attention to the polymer used. A dissolution test is a 
method that can be used to determine the level of solubility or 
release of drugs from oral preparations [5]. There are two 
mechanisms for drug release from solid dispersions, which are 
based on carrier or drug controlled. The carrier controlled 
mechanism begins with the formation of a polymer-rich diffusion 
layer between the dissolution media and the solid dispersion. When 
the dissolution process is mediated by the carrier, the drug diffuses 
first into the polymer-rich layer and then is released to the 
dissolution medium in the form of dissolved or amorphous 
molecules. Whereas the drug controlled mechanism does not form a 
polymer-rich layer due to the high solubility of the carrier in the 
dissolution media so that the drug is immediately dissolved through 
diffusion from solid dispersion to the dissolution media [31]. 
The solid dispersion formula in eight papers that had previously been 
proven to increase the dissolution profile was then tested for an anti-
inflammatory activity to determine the effect of solid dispersion on the 
anti-inflammatory activity of NSAIDs. Anti-inflammatory tests on eight 
of these papers were carried out in vivo using rat or mouse test 
animals that had previously been conditioned according to laboratory 
standards. In addition, the anti-inflammatory test requires edema 
inductor to trigger inflammation in the test animal (table 2). 
 
Table 2: Anti-inflammatory test result of NSAID solid dispersion 
Authors NSAIDs Inflammatory inductor % Inhibition 
Solid dispersion Non-solid dispersion 
6 Ibuprofen Xylene 67.6 45.6 
17 Aceclofenac Carrageenan 52.9 43.5 
29 Meloxicam Formalin 50 2.5 
18 Flubiprofen Caragenan 33.33 24.67 
11 Sulindac Formalin 58 1 
20 a. Mefenamic Acid 
b. Flufenamat Acid 




24 Mefenamic Acid Carrageenan 89.83 74.57 
27 Celecoxib CFA 28 8 
 
Anti-inflammatory test on ibuprofen-urea SD was done by inducing 
xylene in the inner and outer rat ears 30 min after oral 
administration of ibuprofen SD and ibuprofen NSD, so that in this 
study edema measurements in rat ears were carried out by taking 6 
mm portions of the control mouse ears and treatment that describes 
the weight of edema in mice. The weight of edema in control mice 
was 2.3±0.9 mg, in mice with ibuprofen NSD was 1.2±0.4 mg, and in 
mice with ibuprofen SD was 0.7±0.6 mg. Besides that, the percentage 
of inhibition from ibuprofen NSD was 45.6% and the percentage of 
inhibition from ibuprofen SD was 67.6%. Based on the percentage of 
inhibition results it is known that ibuprofen SD provides an increase 
in anti-inflammatory activity by significantly reducing edema due to 
an increase in saturation solubility in the gastrointestinal fluid [6]. 
Research conducted by Jana et al., conducted an anti-inflammatory 
test on aceclofenac SD made in a gel preparation with carbopol 940 
as a gelling agent, so that the aceclofenac gel was applied to the 
backs of mice. The edema inductor used is carrageenan which was 
applied 3 h after administration of the gel by intradermal injection. 
Edema volume was calculated after 3 h of carrageenan induction 
with a plethysmometer. The percentage inhibition results obtained 
were 43.5% and 52.9% in aceclofenac NSD and aceclofenac SD, 
respectively. This shows that with the modification of solid 
dispersion there is an increase in anti-inflammatory activity. 
Carbopol 940 that binds to crospovidone can increase the rate of 
aceclofenac permeation so that it is directly proportional to the 
increase in the amount of aceclofenac in the body and can increase 
the anti-inflammatory response given [17]. In meloxicam solid 
dispersion, an anti-inflammatory test was carried out on rats with 
formalin as an edema inductor given one hour after oral 
administration of meloxicam NSD and meloxicam SD. The results of 
the percentage inhibition of meloxicam SD is 50% after 1.5 h of 
injection of formalin, while the percentage of inhibition on 
meloxicam NSD is 2.5%. This has a correlation with other test 
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results, such as the dissolution test previously described [29]. 
Research conducted by Malipeddi et al. developing a combination of 
solid dispersions and microspheres to form controlled-release 
preparations. However, in accordance with the purpose of this study, 
which is to look at the anti-inflammatory activity of solid 
dispersions, it will only discuss solid dispersions. An anti-
inflammatory test was carried out by inducing carrageenan in rat 
feet after oral administration of flurbiprofen NSD and flurbiprofen 
SD. After 3 h of carrageenan injection, the percentage of inhibition in 
flurbiprofen SD was 33.33%, whereas in flurbiprofen NSD was 
obtained 24.67%. This shows that solid dispersion plays a role in 
increasing flurbiprofen's anti-inflammatory activity [18]. 
Research by Shazly developing a combination of solid dispersions 
and microspheres to form controlled-release preparations. However, 
in accordance with the purpose of this study, which is to look at the 
anti-inflammatory activity of solid dispersions, it will only discuss 
solid dispersions. Anti-inflammatory tests were carried out by 
inducing carrageenan in rat feet after oral administration of 
flurbiprofen NSD and flurbiprofen SD. After 3 h of carrageenan 
injection, the percentage of inhibition in flurbiprofen SD was 
33.33%, whereas in flurbiprofen NSD was obtained 24.67%. This 
shows that solid dispersion plays a role in increasing flurbiprofen's 
anti-inflammatory activity [11]. In other studies, anti-inflammatory 
tests were carried out on solid dispersions of mefenamic acid and 
flufenamic acid. The edema inductor used is carrageenan and is 
given 30 min after oral administration of the sample used. After 4 h 
of carrageenan injection, an inhibition percentage of 87.74% was 
obtained for mefenamic acid SD and 68.09% mefenamic acid NSD. 
While the results of the percentage inhibition of flufenamic acid NSD 
were 55.27% and 81.76% in flufenamic acid SD. This increase in 
anti-inflammatory activity is due to the role of PEG 4000 as a 
solubilizer so as to increase the absorption of mefenamic acid and 
flufenamic acid [20]. Mefenamic acid solid dispersion is made in ODT 
preparations by comparing the anti-inflammatory activity in SD of 
mefenamic acid 20% and 25%. Carrageenan is used as an edema 
inductor that is injected into the rat's feet. After 4 h of carrageenan 
injection, the percentage of inhibition was 74.57%, 86.44%, and 
89.83% for mefenamic acid NSD, mefenamic acid 20% SD, and 
mefenamic acid 25% SD, respectively. Statistically, the difference in 
the percentage of mefenamic acid SD inhibition of 20% and 25% is 
not significant. This shows that the slight change in polymer 
concentration (eudragit EPO) does not significantly change the 
therapeutic activity of mefenamic acid, although in the previous 
dissolution test it was found that the best results on the SD of 
mefenamic acid were 20% and did not differ significantly from the 
SD of mefenamic acid 25% [24]. 
Based on two studies that tested anti-inflammatory activity on 
mefenamic acid that has been modified in a solid dispersion system, 
overall both of them gave an increase in the percentage of inhibition 
both research by Alshehri et al. (2017) and Alshehri et al. (2019). It 
is also known that although mefenamic acid is made in different 
preparations (ODT and not ODT), the presence of a solid dispersion 
system can still increase the anti-inflammatory activity of mefenamic 
acid. This is in line with the increasing dissolution profile in the SD of 
mefenamic acid [20, 24]. There are differences in the research 
conducted by Choi et al. because the test animals are given Complete 
Freund’s Adjuvant (CFA) to condition the mice in the inflammatory 
state of rheumatoid arthritis (RA). The evaluation used to assess 
celecoxib activity as an anti-RA is to look at changes in edema 
volume for 16 d. That is because edema (inflammation) is one of the 
symptoms that is easily observed from RA. The percentage 
inhibition results obtained were 8% and 28% for celecoxib NSD and 
celecoxib SD, respectively. That is because celecoxib SD can inhibit 
the expression of inflammatory markers, such as TNF-α and IL-1β is 
greater than celecoxib NSD [27].  
Based on eight papers that have been described, it is known that the 
modification of solid dispersion can increase the anti-inflammatory 
activity of NSAIDs, this is proportional to the increasing dissolution 
profile which causes an increase in the NSAID bioavailability in the 
body. In addition, solid dispersions are known to inhibit inflammatory 
mediators or markers, such as prostaglandins, TNF-α, and IL-1β which 
are greater than NSAIDs without solid dispersions [11, 17, 20, 24]. 
CONCLUSION 
Modification of solid dispersions can improve the dissolution profile 
of NSAIDs by increasing the wettability of drug particles and causing 
the NSAID to change from crystalline to amorphous. In addition, 
modification of the solid dispersion system can increase the anti-
inflammatory activity of NSAIDs in vivo, as this is proportional to the 
increased dissolution profile leading to increased bioavailability of 
NSAIDs in the body. 
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